|
業務類別
|
Biotechnology |
|
業務概覽
|
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101,a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases. |
| 公司地址
| 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 362-6295 |
| 傳真號碼
| -- |
| 公司網頁
| |
| 員工數量
| 104 |
| Mr. Daniel R. Faga |
President, Chief Executive Officer and Director |
-- |
20/04/2026 |
| Mr. Ajim Tamboli, C.F.A. |
Chief Financial Officer |
-- |
20/04/2026 |
| Mr. Paul F. Lizzul, M.D.,PhD |
Chief Medical Officer |
-- |
27/03/2026 |
| Mr. Benjamin Stone |
Chief Business Officer |
-- |
27/03/2026 |
|
|
| Dr. Rita I. Jain, M.D. |
Director |
27/03/2026 |
| Mr. Daniel R. Faga |
President, Chief Executive Officer and Director |
20/04/2026 |
| Dr. Magda Marquet, PhD |
Director |
27/03/2026 |
| Dr. J. Anthony Ware, M.D. |
Director |
27/03/2026 |
| Dr. Dennis M. Fenton,PhD |
Director |
27/03/2026 |
| Mr. John A. Orwin, M.B.A. |
Chairman of the Board |
27/03/2026 |
| Mr. John P. Schmid |
Director |
27/03/2026 |
|
|
|
|
